Get the Stockscreener App
0.2484
4.57%
-0.0119
After Hours:
.40
0.1516
+61.03%
Silexion Therapeutics Corp stock is traded at $0.2484, with a volume of 35.24M.
It is down -4.57% in the last 24 hours and down -31.53% over the past month.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
See More
Previous Close:
$0.2603
Open:
$0.2622
24h Volume:
35.24M
Relative Volume:
8.59
Market Cap:
$1.38M
Revenue:
-
Net Income/Loss:
$-12.91M
P/E Ratio:
-0.00263
EPS:
-94.5617
Net Cash Flow:
$-12.02M
1W Performance:
-54.35%
1M Performance:
-31.53%
6M Performance:
-97.96%
1Y Performance:
-99.33%
1-Day Range:
$0.2404
$0.276
1-Week Range:
$0.2362
$0.50
52-Week Range:
$0.2362
$42.60
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.2484 | 1.45M | 0 | -12.91M | -12.02M | -94.56 |
VRTX
Vertex Pharmaceuticals Inc
|
527.67 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
197.28 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
752.25 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
972.25 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
201.74 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Form PRE 14A SILEXION THERAPEUTICS CORP For: 26 September By Investing.com - Investing.com India
Price to sales forward of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
Silexion Therapeutics Notified of Nasdaq Bid Price Deficiency, Trading Continues Unaffected - Kalkine Media
Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice - TipRanks
Silexion Therapeutics Corp (SLXNW) Stock Price, News, Quote & History - Yahoo Finance
Why Is the Market Watching Silexion Therapeutics (SLXN)? - kalkinemedia.com
Biotech Pre-Market Movers: TNON, AEON Surge; COO, CDT Slide - RTTNews
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewswire
SLXN Q2 2026 Earnings: Loss Per Share of -$5.17 Misses Estimates by 139.09% as Company Remains Pre-RevenueNew Analyst Coverage - dars.gov.et
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN) - TipRanks
Silexion (SLXNW) Range: Finishes Nearly Flat at $0.01 in Latest Trading; Next Test - dars.gov.et
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal - The Globe and Mail
Silexion Therapeutics Received Notice of Delisting - TradingView
Top Silexion Therapeutics CorpWarrant (SLXNW) Competitors 2026 - MarketBeat
Silexion Therapeutics Executes Reverse Share Split Amid Strain - The Globe and Mail
Silexion Therapeutics Closes Public Offering and Strengthens Equity - The Globe and Mail
Silexion Therapeutics (SLXN) seeks huge share boost and reverse split to stay on Nasdaq - Stock Titan
Silexion Q2 EPS $(5.17) misses $(2.12) estimate; loss widens - scanx.trade
Silexion Therapeutics Raises $35 Million in August Public Offering - Minichart
Silexion Therapeutics Corp 2Q 2026: Net loss $3.55M, EPS $(12.41) — 10-Q Summary - TradingView
Silexion Initiates Phase 2/3 Pancreatic Cancer Trial on July 29 - Minichart
Silexion Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Moomoo
Silexion Therapeutics reports Q2 2026: $3.6M Q2 net loss, $2.2M cash at June 30 - TradingView
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Press Release: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Silexion Completes 1-for-10 Reverse Share Split - Minichart
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Nigeria
Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants - Stock Titan
Silexion Therapeutics Corp SEC Filing (Aug 12, 2026) - Stock Titan
Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell - marketscreener.com
Silexion Therapeutics prices $2.5M public offering at $0.65 By Investing.com - Investing.com India
Silexion prices $2.5M offering to fund KRAS cancer trial - Dealroom
Silexion Therapeutics prices $2.5M public offering at $0.65 - Investing.com
Silexion Intends to Use Offering Proceeds for Pancreatic Trial - Stock Titan
Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants - Quiver Quantitative
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire
SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls 31%Earnings Revision Upgrade - dars.gov.et
SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, Yet Shares Tumble 29%GAAP Earnings Report - dars.gov.et
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - TipRanks
Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - Benzinga
Immunotherapy's Biggest Blind Spot Is A $7 Billion Market. Silexion May Have A Way In (NASDAQ: SLXN) - Menafn
Form 8K Silexion Therapeutics Corp For: 10 August By Investing.com - Investing.com South Africa
Silexion Updates SIL204 Clinical and Regulatory Roadmap - tipranks.com
Silexion Therapeutics (SLXN US): Synthetic Expert Call Transcript (10 Aug 2026) - Smartkarma
Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - Bitget
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Hold Rating - 富途牛牛
IPO Databook: Silexion Therapeutics (SLXN US)Aug 2026 - Smartkarma
Silexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock Titan
Silexion Therapeutics Warrant (SLXNW) Holds Flat at $0.02 as Trading Range CompressesAdvance Decline Line - careplusvn.com
Silexion unveils key SIL204 KRAS preclinical findings - TipRanks
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):